Cargando…
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
Neuroendocrine tumors (NETs) are rare neoplasms with a wide spectrum of clinical behavior, from the long survival of well-differentiated NETs to the dismal prognosis of high-grade neuroendocrine carcinomas (NECs), being G3 NETs a recently recognized intermediate entity. While the role of chemotherap...
Autores principales: | Zappi, Arianna, Persano, Irene, Galvani, Linda, Parlagreco, Elena, Andrini, Elisa, Campana, Davide, Brizzi, Maria Pia, Lamberti, Giuseppe, La Salvia, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861419/ https://www.ncbi.nlm.nih.gov/pubmed/36675645 http://dx.doi.org/10.3390/jcm12020717 |
Ejemplares similares
-
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)
por: Lamberti, Giuseppe, et al.
Publicado: (2023) -
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors
por: Brighi, Nicole, et al.
Publicado: (2023) -
An Update on Appendiceal Neuroendocrine Tumors
por: Andrini, Elisa, et al.
Publicado: (2023) -
Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs
por: Laffi, Alice, et al.
Publicado: (2023) -
Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)
por: Apostolidis, Leonidas, et al.
Publicado: (2021)